Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNT trial: carboplatin versus docetaxel in advanced triple-negative breast cancer
ISRCTN97330959Phase 3Completed
- Sponsor
- The Institute of Cancer Research
- Start
- Jan 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of carboplatin and docetaxel in triple-negative breast cancer (TNBC), sponsored by The Institute of Cancer Research. Primary endpoint: Response. Started Jan 2008; status: completed.
02
Drugs
carboplatindocetaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ISRCTN97330959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN97330959.